Theranexus SA - Asset Resilience Ratio
Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. Check Theranexus SA strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALTHX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.02 Million | 66.61% |
| Total Liquid Assets | €7.02 Million | 66.61% |
Asset Resilience Insights
- Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theranexus SA Industry Peers by Asset Resilience Ratio
Compare Theranexus SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Theranexus SA (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Theranexus SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.61% | €7.02 Million ≈ $8.21 Million |
€10.54 Million ≈ $12.33 Million |
+53.12pp |
| 2024-12-31 | 13.49% | €504.56K ≈ $589.88K |
€3.74 Million ≈ $4.37 Million |
-69.47pp |
| 2021-12-31 | 82.97% | €14.01 Million ≈ $16.38 Million |
€16.89 Million ≈ $19.75 Million |
+54.34pp |
| 2020-12-31 | 28.63% | €5.00 Million ≈ $5.85 Million |
€17.47 Million ≈ $20.42 Million |
-49.79pp |
| 2019-12-31 | 78.42% | €12.05 Million ≈ $14.09 Million |
€15.37 Million ≈ $17.97 Million |
-6.65pp |
| 2018-12-31 | 85.07% | €16.03 Million ≈ $18.75 Million |
€18.85 Million ≈ $22.04 Million |
+72.96pp |
| 2016-12-31 | 12.11% | €348.87K ≈ $407.86K |
€2.88 Million ≈ $3.37 Million |
-39.08pp |
| 2015-12-31 | 51.19% | €1.40 Million ≈ $1.63 Million |
€2.73 Million ≈ $3.19 Million |
-- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more